多发性骨髓瘤中的间充质干细胞:治疗工具还是治疗靶点?
多发性骨髓瘤(MM)是恶性浆细胞疾病,骨髓间充质干细胞(MSCs)是骨髓基质主要干细胞群,可迁移至肿瘤部位并可能调节肿瘤生长与转移,此问题尚有争议。近期研究显示MM患者来源MSCs存在功能异常,提示MSCs不仅是骨髓微环境旁观者,而是疾病病理生理的积极参与者。本综述聚焦MSCs在MM中的生物学作用及基于MSC治疗的潜在应用。
要点
- MM细胞与骨髓基质微环境形成复杂交互网络,促进MM细胞存活、增殖和化疗耐药。
- MSCs可迁移至原发肿瘤和转移部位,可能调节肿瘤生长和转移,但该问题仍有争议且未充分理解。
- MM患者来源MSCs存在功能异常,提示MSCs是MM病理生理的积极参与者而非旁观者。
核心结论
- MSCs与MM细胞的复杂相互作用似乎对MM发生和疾病结局至关重要。
- 本综述聚焦MSCs在MM中的生物学作用及基于MSC治疗的潜在应用。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- MM是恶性浆细胞疾病,特征为肿瘤细胞与骨髓基质微环境形成复杂交互网络,促进MM细胞存活、增殖和化疗耐药。
- MSCs是骨髓基质主要干细胞群,可分化为成纤维细胞、脂肪细胞、软骨细胞和成骨细胞。
- MSCs可迁移至原发肿瘤和转移部位,可能调节肿瘤生长和转移,但该问题仍有争议且未充分理解。
- 近期多项研究显示MM患者来源MSCs存在功能异常,提示MSCs不仅是骨髓微环境旁观者,而是疾病病理生理的积极参与者。
- MSCs与MM细胞的复杂相互作用似乎对MM发生和疾病结局至关重要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a malignant plasma cell (PC) disorder, characterized by a complex interactive network of tumour cells and the bone marrow (BM) stromal microenvironment, contributing to MM cell survival, proliferation and chemoresistance. Mesenchymal stem cells (MSCs) represent the predominant stem cell population of the bone marrow stroma, capable of differentiating into multiple cell lineages, including fibroblasts, adipocytes, chondrocytes and osteoblasts. MSCs can migrate towards primary tumours and metastatic sites, implying that these cells might modulate tumour growth and metastasis. However, this issue remains controversial and is not well understood. Interestingly, several recent studies have shown functional abnormalities of MM patient-derived MSCs indicating that MSCs are not just by-standers in the BM microenvironment but rather active players in the pathophysiology of this disease. It appears that the complex interaction of MSCs and MM cells is critical for MM development and disease outcome. This review will focus on the current understanding of the biological role of MSCs in MM as well as the potential utility of MSC-based therapies in this malignancy.
引用
- Xu S, De Veirman K, De Becker A, et al. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia. 2018. PMID: 29535427. doi:10.1038/s41375-018-0061-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。